Cancer Research and Treatment

Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion

Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, Masato Chiba, Masaki Shimoji, Masaoki Ito, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani, Tetsuya Mitsudomi

Journal of Thoracic Oncology.2024; 19(1): 71. CrossRef

Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens

Azadeh Nasrazadani, Juan Luis Gomez Marti, Kate Lathrop, Alvaro Restrepo, Szu-Yun Leu, Gajanan Bhat, Adam Brufsky

Breast Cancer Research and Treatment.2024;[Epub] CrossRef

Emerging Targeted Therapies for HER2-Positive Breast Cancer

María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS

Shuanghu Wang, Mengming Xia, Yu Wang, Zebei Lu, Peiwu Geng, Dapeng Dai, Yunfang Zhou, Qingjun Wu

Neratinib for HER2-positive breast cancer with an overlooked option

Liting Guo, Weiwei Shao, Chenfei Zhou, Hui Yang, Liu Yang, Qu Cai, Junqing Wang, Yan Shi, Lei Huang, Jun Zhang

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing

Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Kenichi Suda, Kazuko Sakai, Hidenori Sato, Tetsuya Mitsudomi

JTO Clinical and Research Reports.2023; 4(9): 100554. CrossRef

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer

Arnaldo Marín, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker

In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes

Salman Alamery, Anfal AlAjmi, Tanveer A. Wani, Seema Zargar

Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy

María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, Maximino Redondo, Teresa Téllez

Catarina Lopes Fernandes, Diogo J. Silva, Alexandra Mesquita

Trastuzumab deruxtecan for HER2+ advanced breast cancer

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V. Heymach, Mark A. Socinski

Journal of Clinical Oncology.2022; 40(7): 710. CrossRef

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan

Tailoring antiHer2 treatment strategies in breast cancer and beyond

Palma Fedele, Valeria Sanna, Anna Natalizia Santoro, Maria Laura Iaia, Alessandro Fancellu

Current Problems in Cancer.2022; 46(5): 100892. CrossRef

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives

Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao

Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches

Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman

Journal of Personalized Medicine.2022; 12(10): 1651. CrossRef

An ultra-performance LC–MS/MS method for determination of JRF103 in human plasma: application in first in-patient study

Ying Jin, Xiangjie Di, Lisha Fu, Mengyu Zhang, Neng Qiu, Runhan Liu, Fangqun Li, Xiaohui Qi, Xiaoxu Wang, Yongsheng Wang, Zhenlei Wang

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake

Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino

Critical Reviews in Oncology/Hematology.2021; 160: 103299. CrossRef

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro

Weiping Ji, Jiquan Shen, Bo Wang, Feifei Chen, Deru Meng, Shuanghu Wang, Dapeng Dai, Yunfang Zhou, Changxiong Wang, Quan Zhou

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib

Breast Cancer: Targets and Therapy.2021; Volume 13: 361. CrossRef

Current therapeutic options for gastric adenocarcinoma

C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad

Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer

Barbara Melosky, Paul Wheatley-Price, Rosalyn A. Juergens, Adrian Sacher, Natasha B. Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B. Card, Quincy Chu

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer

Chia-Jung Li, Yen-Dun Tony Tzeng, Yi-Han Chiu, Hung-Yu Lin, Ming-Feng Hou, Pei-Yi Chu

Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview

Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors

Seyed-Omar Zaraei, Rawan M. Sbenati, Nour N. Alach, Hanan S. Anbar, Randa El-Gamal, Hamadeh Tarazi, Mahmoud K. Shehata, Mohammed S. Abdel-Maksoud, Chang-Hyun Oh, Mohammed I. El-Gamal

European Journal of Medicinal Chemistry.2021; 224: 113674. CrossRef

Breast Cancer Treatments: Updates and New Challenges

Journal of Personalized Medicine.2021; 11(8): 808. CrossRef

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial

Akira Hamada, Kenichi Suda, Takamasa Koga, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuro Uchida, Tetsuya Mitsudomi

HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy

Ioannis A. Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N. Syrigos

Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma

Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang

Journal of Thoracic Oncology.2020; 15(6): 962. CrossRef

Drug resistance to targeted therapeutic strategies in non-small cell lung cancer

Pharmacology & Therapeutics.2020; 206: 107438. CrossRef

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard

Critical Reviews in Oncology/Hematology.2020; 148: 102906. CrossRef

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma

Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang, Xiaoyan Ma, Minghui Wang, Wenjing Wang, Songhui Zhao, Kai Wang, Song Gao, Li Zhang

Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study

Teresa Moran, Alvaro Taus, Edurne Arriola, Carlos Aguado, Manuel Dómine, Ana Gómez Rueda, Antonio Calles, Susana Cedrés, Nuria Viñolas, Dolores Isla, Ramón Palmero, María Sereno, Victor Diaz, Oscar Juan, Raquel Marsé, Paloma Martín Martorell, José Miguel

HER2-positive advanced breast cancer treatment in 2020

Marcelle G. Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja

Cancer Treatment Reviews.2020; 88: 102033. CrossRef

New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?

Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, Anthony Gonçalves

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib

Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang, Shucai Zhang

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib

Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park

Breast Cancer Research and Treatment.2020; 184(3): 743. CrossRef

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Jordi Remon, Lizza E.L. Hendriks, Andres F. Cardona, Benjamin Besse

Cancer Treatment Reviews.2020; 90: 102105. CrossRef

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma

Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni

Critical Reviews in Oncology/Hematology.2020; 156: 103119. CrossRef

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer

Technology in Cancer Research & Treatment.2020; 19: 153303382096214. CrossRef

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells

Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang

Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine

Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo

Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use

Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry

European Journal of Medicinal Chemistry.2019; 170: 55. CrossRef

Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer

Tae-Yong Kim, Hye Sook Han, Keun-Wook Lee, Dae Young Zang, Sun Young Rha, Young Iee Park, Jin-Soo Kim, Kyung-Hun Lee, Se Hoon Park, Eun-Kee Song, Soo-A Jung, NaMi Lee, Yeul Hong Kim, Jae Yong Cho, Yung-Jue Bang

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown

Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positi

Ji‐Yeon Kim, Eunjin Lee, Kyunghee Park, Hae Hyun Jung, Woong‐Yang Park, Kyung‐Hun Lee, Joohyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee Hyun Kim, Ki Hyeong Lee, Seock‐Ah Im, Yeon Hee Park

International Journal of Cancer.2019; 145(6): 1669. CrossRef

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers

Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study

Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Makoto Suzuki, Pasi A. Jänne, Tetsuya Mitsudomi

A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial

Yeon Hee Park, Kyung‐Hun Lee, Joo Hyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee‐Hyun Kim, Ki Hyeong Lee, Jin Seok Ahn, Tae‐Yong Kim, Gun Min Kim, In Hae Park, Sung‐Bae Kim, Se Hyun Kim, Hye Sook Han, Young‐Hyuck Im, Jin‐Hee Ahn, Jung‐Yong Kim, Jahoon Kang

International Journal of Cancer.2018; 143(12): 3240. CrossRef

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa

Clinical Cancer Research.2018; 24(24): 6548. CrossRef